- Home
- NCTY vs TIL Comparison
NCTY vs TIL Comparison
Compare NCTY & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | TIL |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 52.2M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCTY | TIL |
|---|---|---|
| Price | $2.54 | $6.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.7K | ★ 58.7K |
| Earning Date | 11-24-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $5.56 |
| 52 Week High | $8.36 | $16.00 |
Technical Indicators
Market Signals| Indicator | NCTY | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 49.78 |
| Support Level | N/A | $5.56 |
| Resistance Level | $5.48 | $7.75 |
| Average True Range (ATR) | 0.22 | 0.43 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 25.52 | 63.58 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.